Clinical Trials
67
Trial Phases
4 Phases
Drug Approvals
10
Drug Approvals
Recombinant Coagulation Factor VIII for Injection
- Product Name
- 绿茵芷
- Approval Number
- 国药准字SJ20210022
- Approval Date
- Aug 5, 2021
Clinical Trials
Distribution across different clinical trial phases (63 trials with phase data)• Click on a phase to view related trials
Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella Vaccination
- Conditions
- Varicella
- First Posted Date
- 2022-06-16
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- Green Cross Corporation
- Target Recruit Count
- 230
- Registration Number
- NCT05422508
- Locations
- 🇰🇷
Korea University Ansan Hospital, Ansan, Korea, Republic of
COVIDIG (COVID-19 Hyper-ImmunoGlobulin)
- Conditions
- Covid19
- First Posted Date
- 2020-09-18
- Last Posted Date
- 2021-08-24
- Lead Sponsor
- Green Cross Corporation
- Target Recruit Count
- 63
- Registration Number
- NCT04555148
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3111 in Healthy Adults
- Conditions
- DiphtheriaWhooping CoughTetanus
- First Posted Date
- 2020-01-23
- Last Posted Date
- 2020-01-23
- Lead Sponsor
- Green Cross Corporation
- Target Recruit Count
- 213
- Registration Number
- NCT04238975
- Locations
- 🇰🇷
The Catholic Univ. of Korea Eunpyeong St. Mary's Hospital, Seoul, Korea, Republic of
Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis:
- First Posted Date
- 2019-11-25
- Last Posted Date
- 2020-06-30
- Lead Sponsor
- Green Cross Corporation
- Target Recruit Count
- 23
- Registration Number
- NCT04175522
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Study of Combined Therapy IVIG-SN 10% and Acetylsalicylic Acid in Kawasaki Disease
- Conditions
- Kawasaki Disease
- Interventions
- First Posted Date
- 2019-07-01
- Last Posted Date
- 2020-05-21
- Lead Sponsor
- Green Cross Corporation
- Target Recruit Count
- 45
- Registration Number
- NCT04003844
- Locations
- 🇰🇷
Hallym University Sacred Heart Hospital, Anyang, Korea, Republic of
🇰🇷Asan Medical Center, Seoul, Korea, Republic of
🇰🇷Kyung Hee University Hospital at Gangdong, Seoul, Korea, Republic of
- Prev
- 1
- 2
- 3
- 4
- 5
- 13
- Next
News
South Korea Positions Life Sciences Sector for Global Leadership with Strategic Five-Point Plan
• South Korea's government has unveiled an ambitious five-point strategy to revolutionize its bio-health industry, focusing on innovation in medical services, export growth, and AI-driven R&D advancement. • The country's life sciences sector is experiencing rapid growth through substantial public-private investments, supported by advanced infrastructure and a highly skilled STEM workforce. • Major players like Samsung Biologics, LG Chem, and Celltrion are driving industry growth, while government initiatives provide robust support for biotech startups and research development.